Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
RNA Interference01:23

RNA Interference

26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy.

Cancers·2026
Same author

Practical Management of Headaches in Patients With Primary and Secondary Brain Tumors.

Journal of pain and symptom management·2026
Same author

Genomic landscape and precision therapy in prostate cancer: current status and future directions.

NPJ precision oncology·2026
Same author

<i>BRCA2</i> and <i>NF2</i>-Mutated High-Grade Renal Cell Carcinoma: A Case Report and Literature Review.

International journal of surgical pathology·2026
Same author

Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma.

Nature cancer·2026
Same author

Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors.

Journal for immunotherapy of cancer·2025
Same journal

Spatial accessibility analysis of vaccination units in Gansu Province, China (2025).

Human vaccines & immunotherapeutics·2026
Same journal

Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study.

Human vaccines & immunotherapeutics·2026
Same journal

How vaccine research took me on an international journey.

Human vaccines & immunotherapeutics·2026
Same journal

Health-related quality of life and adverse events during 14 days after receiving a live-attenuated influenza vaccine in Japanese children 4-15 years of age.

Human vaccines & immunotherapeutics·2026
Same journal

Immunological insights into why pertussis continues to be endemic.

Human vaccines & immunotherapeutics·2026
Same journal

Mapping the global landscape of research on immune checkpoint inhibitor-associated cardiotoxicity: A quantitative and visualized bibliometric study (2016-2025).

Human vaccines & immunotherapeutics·2026
See all related articles

Related Experiment Video

Updated: Sep 10, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791

Systemic mRNA aggregates elicit immunologic reprogramming that unlocks anti-cancer immunity.

Hector R Mendez-Gomez1, John A Ligon2, Ashley P Ghiaseddin1

  • 1Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.

Human Vaccines & Immunotherapeutics
|August 19, 2025
PubMed
Summary
This summary is machine-generated.

Novel mRNA-loaded lipid particle aggregates (RNA-LPAs) reprogram the tumor microenvironment and periphery. This approach generates cancer-specific immunity to combat difficult-to-treat tumors like glioblastoma.

Keywords:
cancerimmunotherapymRNA vaccines

More Related Videos

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.5K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

Related Experiment Videos

Last Updated: Sep 10, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.5K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

Area of Science:

  • Immunology
  • Oncology
  • Nanotechnology

Background:

  • Cancer immunotherapy faces challenges with intratumoral immunosuppression and peripheral tolerance.
  • Immunologically 'cold' tumors, such as glioblastoma, are particularly resistant to current treatments.

Purpose of the Study:

  • To investigate a novel approach for cancer immunotherapy using mRNA-loaded lipid particle aggregates (RNA-LPAs).
  • To assess the ability of RNA-LPAs to overcome immunosuppression and induce cancer-specific immunity.

Main Methods:

  • Intravenous administration of mRNA-loaded lipid particle aggregates (RNA-LPAs).
  • Reprogramming of the tumor microenvironment and peripheral immune compartments.

Main Results:

  • RNA-LPAs successfully reprogrammed both the tumor microenvironment and periphery.
  • Simultaneous generation of cancer-specific immunity was achieved.

Conclusions:

  • Intravenously administered RNA-LPAs represent a promising strategy for overcoming immunosuppression in cancer.
  • This approach holds potential for treating 'cold' tumors by enabling robust, cancer-specific immune responses.